Germany stands at the epicenter of European biotechnology and medical device innovation. As a global leader in healthcare technology, the German market demands Nucleic Acid Detection Systems that not only meet stringent IVDR (In Vitro Diagnostic Regulation) standards but also integrate seamlessly into highly automated "Industry 4.0" laboratory environments.
The transition from traditional diagnostic methods to rapid molecular analysis—driven by PCR, NGS (Next-Generation Sequencing), and CRISPR-based detection—has positioned Germany as a primary hub for global procurement. Our systems are engineered to support the high-precision requirements of German clinical labs, research institutes in Berlin, and pharmaceutical giants in the Rhine-Neckar region.
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, the company is headquartered in Shenzhen, China, a leading center for biotechnology innovation, medical device development, and advanced manufacturing.
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, public health organizations, and biotechnology companies worldwide.
In Germany, the decentralized testing trend is accelerating. Portable 4-channel PCR systems are increasingly used in local clinics and veterinary practices to provide real-time results, reducing the logistics load on central labs in cities like Hamburg and Frankfurt.
The integration of AI in nucleic acid detection—specifically for defect detection in consumables and automated result interpretation—is no longer a "future" concept. Our SV1300 series utilizes high-speed vision systems to ensure zero-defect packaging for diagnostic reagents, aligning with the German philosophy of "Null-Fehler-Qualität" (Zero-Error Quality).
The new EU IVDR 2017/746 has raised the bar for reliability and clinical evidence. Our systems are developed with comprehensive technical documentation to assist German importers in meeting regulatory hurdles efficiently.
We provide end-to-end solutions that span from initial sample preparation to final analysis, ensuring data integrity and operational safety.
High-throughput extraction systems like the BK-Autohs96 allow German labs to process up to 96 samples simultaneously with minimal human intervention.
Pharmaceutical-grade sterile isolation and negative pressure systems (Marya series) for safe handling of high-pathogenicity samples.
Specialized portable QPCR systems designed for Germany's expanding veterinary diagnostic network, ensuring rapid livestock and pet health screening.
The company's product portfolio includes molecular diagnostic analysis systems, nucleic acid testing platforms, genetic analysis systems, pathogen detection solutions, biomarker analysis equipment, automated laboratory testing systems, and precision medicine support technologies. By integrating advanced automation, data management capabilities, and laboratory workflow optimization, BioX Medical develops solutions designed to improve testing efficiency, analytical accuracy, and operational reliability.
Supported by a multidisciplinary team of engineers, laboratory specialists, and quality management professionals, the company continuously invests in innovation and product development. Comprehensive quality control procedures are implemented throughout design, manufacturing, testing, and inspection processes to ensure consistent performance and compliance with international industry standards.
Shenzhen BioX Medical Co., Ltd. serves customers across Europe, North America, Asia-Pacific, the Middle East, Latin America, and Africa. The company also provides flexible OEM and ODM services for distributors, diagnostic companies, and healthcare organizations seeking customized molecular testing solutions.
Committed to advancing modern laboratory technologies, BioX Medical focuses on delivering reliable, scalable, and innovative diagnostic systems that support disease detection, genetic analysis, clinical research, and precision healthcare initiatives. Our future roadmap for the German market includes:
Yes, our R&D and manufacturing processes are aligned with ISO 13485 standards, and we provide comprehensive technical files to support CE-IVD marking as required by European Union regulations.
Typically, for standard orders, the lead time is 2-4 weeks. We offer air freight options to major German hubs like Frankfurt and Munich for urgent diagnostic requirements.
Absolutely. Our systems feature open API protocols and standardized data output formats (like CSV, JSON, or HL7) to ensure seamless integration with modern German LIMS and AI diagnostic platforms.
We support our German distributors with extensive training modules, remote diagnostic tools, and a 24/7 technical hotline to ensure minimal downtime for critical testing environments.
Join the network of German laboratories upgrading to BioX Medical's high-precision nucleic acid detection systems.
BioX Medical
